Zhongyuan Union Cell & Gene Engineering Corporation Overview

  • Status
  • Public

  • Employees
  • 1,935

Employees

  • Stock Symbol
  • 600645

Stock Symbol

  • Investments
  • 12

  • Share Price
  • $2.51
  • (As of Friday Closing)

Zhongyuan Union Cell & Gene Engineering Corporation General Information

Description

Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in The research, development, production and sales of cell detection preparation and storage, gene detection, in vitro diagnostic reagents and instruments, as well as the research, development, production and sales of biological genes, proteins, antibodies, pharmaceutical intermediates and experimental complexes.

Contact Information

Website
www.vcanbio.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Room 406, No. 45 Doungjiu Avenue
  • Tianjin Airport Economic Zone
  • Tianjin, 300304
  • China
+86 022
Primary Industry
Biotechnology
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Room 406, No. 45 Doungjiu Avenue
  • Tianjin Airport Economic Zone
  • Tianjin, 300304
  • China
+86 022

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zhongyuan Union Cell & Gene Engineering Corporation Stock Performance

As of 13-Nov-2026, Zhongyuan Union Cell & Gene Engineering Corporation’s stock price is $2.51. Its current market cap is $1.18B with 468M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.51 $2.60 $2.39 - $4.79 $1.18B 468M 10.3M $0.03

Zhongyuan Union Cell & Gene Engineering Corporation Financials Summary

As of 30-Sep-2026, Zhongyuan Union Cell & Gene Engineering Corporation has a trailing 12-month revenue of $200M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,100,415 1,465,262 1,064,183 1,153,583
Revenue 199,552 202,320 220,951 224,700
EBITDA 25,401 41,142 35,415 34,986
Net Income 16,327 15,829 13,985 15,047
Total Assets 797,774 756,393 719,024 763,388
Total Debt 9,647 9,815 15,363 16,347
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zhongyuan Union Cell & Gene Engineering Corporation Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zhongyuan Union Cell & Gene Engineering Corporation Investments & Acquisitions (12)

Zhongyuan Union Cell & Gene Engineering Corporation’s most recent deal was a Later Stage VC with Juventas (Drug Discovery) for . The deal was made on 25-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Juventas (Drug Discovery) 25-Jun-2023 Later Stage VC Drug Discovery
Precision Medicine Industry Innovation Center 03-Aug-2022 Secondary Transaction - Private Biotechnology
Zhongyuan Jisheng 16-Feb-2022 Merger/Acquisition Biotechnology
Juventas (Drug Discovery) 13-Dec-2018 Early Stage VC Drug Discovery
Origene 13-Feb-2017 Merger/Acquisition Discovery Tools (Healthcare)
You’re viewing 5 of 12 investments and acquisitions. Get the full list »

Zhongyuan Union Cell & Gene Engineering Corporation ESG

Risk Overview

Risk Rating

Updated April, 30, 2024

27.64 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,999

Rank

Percentile

Pharmaceuticals

Industry

of 952

Rank

Percentile

Biotechnology

Subindustry

of 444

Rank

Percentile

To view Zhongyuan Union Cell & Gene Engineering Corporation’s complete esg history, request access »

Zhongyuan Union Cell & Gene Engineering Corporation Exits (2)

Zhongyuan Union Cell & Gene Engineering Corporation’s most recent exit was on 19-Sep-2016 from Genetron Health. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Genetron Health 19-Sep-2016 Completed
  • 6 buyers
Aeon Therapeutics 01-Jan-2002 Joint Venture Completed
  • 3 buyers
To view Zhongyuan Union Cell & Gene Engineering Corporation’s complete exits history, request access »

Zhongyuan Union Cell & Gene Engineering Corporation Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Zhongyuan Jisheng Shanghai, China 2021
Origene Rockville, MD 1996
Shanghai Zhicheng Biotechnology Pudong, China 1995

Zhongyuan Union Cell & Gene Engineering Corporation FAQs

  • Where is Zhongyuan Union Cell & Gene Engineering Corporation headquartered?

    Zhongyuan Union Cell & Gene Engineering Corporation is headquartered in Tianjin, China.

  • What is the size of Zhongyuan Union Cell & Gene Engineering Corporation?

    Zhongyuan Union Cell & Gene Engineering Corporation has 1,935 total employees.

  • What industry is Zhongyuan Union Cell & Gene Engineering Corporation in?

    Zhongyuan Union Cell & Gene Engineering Corporation’s primary industry is Biotechnology.

  • Is Zhongyuan Union Cell & Gene Engineering Corporation a private or public company?

    Zhongyuan Union Cell & Gene Engineering Corporation is a Public company.

  • What is Zhongyuan Union Cell & Gene Engineering Corporation’s stock symbol?

    The ticker symbol for Zhongyuan Union Cell & Gene Engineering Corporation is 600645.

  • What is the current stock price of Zhongyuan Union Cell & Gene Engineering Corporation?

    As of 13-Nov-2026 the stock price of Zhongyuan Union Cell & Gene Engineering Corporation is $2.51.

  • What is the current market cap of Zhongyuan Union Cell & Gene Engineering Corporation?

    The current market capitalization of Zhongyuan Union Cell & Gene Engineering Corporation is $1.18B.

  • What is Zhongyuan Union Cell & Gene Engineering Corporation’s current revenue?

    The trailing twelve month revenue for Zhongyuan Union Cell & Gene Engineering Corporation is $200M.

  • What is Zhongyuan Union Cell & Gene Engineering Corporation’s annual earnings per share (EPS)?

    Zhongyuan Union Cell & Gene Engineering Corporation’s EPS for 12 months was $0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process